Table 1.
Identification of differentially expressed phosphoproteins (> two-fold decrease ↓ by OT treatment in MIA PaCa-2 cells) by MALDI-TOF/TOF MS
| Spot #a |
Accession Number |
Protein Name |
Scoreb | m/z | Pep(score)c | Sequence coverage (%) |
Charge | Matched/ Unmatchedd |
Calculated MW/pI |
Possible Role | Turnover Rolee |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Phosphor proteins identified | |||||||||||
| 2255.99 |
154HNDDEQYAWESSAGGSFTVR173 (59) |
||||||||||
| 1 | P07900 | ↓Hsp90α | 360 | 2374.179 | 368VFIMDNCEELIPEYLNFIR386 (49) | 42 | mono | 26/66 | 84607/4.94 | Related to tumor growth (24-26, 36) |
0.67 |
| 91348.6 | 328HFSVEGQLEFR338 (20) | ||||||||||
| 2415.210 | 368VFIMDNCEELIPEYLNFIR386 (52) | ||||||||||
| 1342.729 | 536EAQLYAAQAHLK547 (75) | ||||||||||
| 1610.906 | 538EIEELKELLPEIR650 (79) | ||||||||||
| 2 | P49321 | ↓ NASP | 290 | 1988.813 | 77YGETANECGEAFFFYGK93 (61) | 26 | mono | 14/25 | 85186/4.26 | Cellular proliferation (37) |
0.89 |
| 2144.032 | 698KPTDGASSSNCVTDISHLVR717 (89) | ||||||||||
| 1423.788 | 21LFQVEYAIEAIK32 (67) | ||||||||||
| 3 | P28066 | ↓ PSMA5 | 180 | 12084.05 | 67IVEIDAHIGCAMSGLIADAK86 (76) | 39 | mono | 7/39 | 26394/4/74 | H1 hinker histone chaperone that is required for cell proliferation (38) |
0.56 |
| 2162.975 |
150GPQLFHMDPSGTFVQCDAR168 (53) |
||||||||||
| 1819.83 | 278MTDQEAIQDLWQWR291 (60) | ||||||||||
| 4* | P06748 | ↓ NPM | 116 | 2227.22 |
81MSVQPTVSLGGFEITPPVVLR101 (51) |
11 | mono | 3/ | 32555/4.64 | anti-apoptosis (39) |
0.67 |
| 1568.730 | 33VDNDENEHQLSLR45 (40) | ||||||||||
| 5 | P09211 | ↓ GSTP1 | 118 | 1337.55 | 2PPYTVVYFPVR12 (34) | 30 | mono | 4/27 | 23341/5.42 | anti-apoptosis (40) |
0.72 |
| 1883.7 | 56FQDGDLTLYQSNTILR71 (84) | ||||||||||
| 1684.940 | 430AAVEEGIVLGGGCALLR446 (46) | ||||||||||
| 6* | P10809 | ↑ HSP60 | 151 | 2365.335 |
269KPLVIIAEDVDGEALSTLVLNR290 (54) |
11 | mono | 3/ | 61016/5.7 | Regulator in cancer Progression (41) |
0.54 |
| 2560.26 |
97LVQDVANNTNEEAGDGTTTATV LAR121 (67) |
||||||||||
| 1370.689 | 472ELSDFISYLQR482 (80) | ||||||||||
| 7 | P30101 | ↓ PDIA3 | 170 | 91664.75 | 434MDATANDVPSPYEVR448 (36) | 26 | mono | 12/23 | 56747/5.98 | ER stress related (42) |
0.45 |
| 2575.29 |
306TFSHELSDFGLESTAGEIPVVAIR 329 (54) |
||||||||||
| 1896.100 | 248VLALSVETDYTFPLAEK264 (31) | ||||||||||
| 8 | P05388 | ↓ RPLP0 | 90 | 2787.70 |
221NVASVCLQIGYPTVASVPHSIIN GYK246 (23) |
31 | mono | 6/35 | 34252/5.71 | Cancer cell proliferation (43) |
0.72 |
| 1624.790 | 187DYGVYLEDSGHTLR200 (89) | ||||||||||
| 9* | Q13162 | ↓ PRDX4 | 167 | 2443.082 |
46TREEECHFYAGGQVYPGEASR66 (68) |
7 | mono | 2/ | 30521/5.86 | Promote cancer cell growth (44, 45) |
0.67 |
| 1085.600 | 98LPFPIIDDR106 (60) | ||||||||||
| 1395.690 | 42DFTPVCTTELGR53 (87) | ||||||||||
| 10 | P30041 | ↓ PRDX6 | 452 | 1582.72 | 85DINAYNCEEPTEK97 (48) | 32 | mono | 5/30 | 25019/6.0 | Cancer cell proliferation (45) |
0.73 |
| 2031.1 | 25FHDFLGDSWGILFSHPR41 (56) | ||||||||||
| 2098.150 |
2PGGLLLGDVAPNFEANTTVGR22 (111) |
||||||||||
| 960.3980 | 21DWYPHSR27 (43) | ||||||||||
| 11 | P04792 | ↓ HSP27 | 231 | 1163.610 | 28LFDQAFGLPR37 (74) | 58 | mono | 12/57 | 22768/5.9 | Promote tumor growth (45) and drug resistance(46) |
0.66 |
| 1783.920 | 97VSLDVNHFAPDELTVK112 (58) | ||||||||||
| 1905.98 | 172LATQSNEITIPVTFESR188 (57) | ||||||||||
| 1256.65 | 131YLAEFATGNDR141 (42) | ||||||||||
| 12 | P62258 | ↓14-3-3E | 306 | 2088.020 |
197AAFDDAIAELDTLSEESYK215 (96) |
59 | mono | 5/12 | 29155/4.63 | Cell cycle progression and tumor growth (47) |
0.63 |
| 2331.26 |
171LGLALNFSVFYYEILNSPDR190 (60) |
||||||||||
| 1820 | 154AASDIAMTELPPTHPIR170 (75) | ||||||||||
As labeled on the 2-D gel (see Figure. 2).
Molecular Weight Search (MOWSE) scores obtained by the combined search (PMF and LIFT data) that were signed to specific protein identity using Mascot engine.
Peptides identified by Ultraflex MALDI-TOF/TOF in “LIFT” mode, and individual peptide score (LIFT data) in the bracket. The superscript number represents the start and end amino acid.
Number of masses matched and not matched for peptide fingerprint data.
Protein turnover rate was calculated according to a newly developed modified (5, 6).
Only LIFT data is available for sequence coverage and masses matched or unmatched calculation.